健康女婴小青春期及青春期过渡期与性早熟女童的血清DLK1水平
三项纵向研究评估健康女婴、健康围青春期女童及中枢性性早熟女童接受GnRHa治疗前后循环DLK1的变化。健康女婴DLK1在出生第一年显著下降(17.6降至9.9 ng/mL,P=0.020),且与出生体重和体脂百分比负相关;青春期过渡期DLK1下降幅度较小;GnRHa治疗不影响DLK1水平。作者认为DLK1因个体间变异大,不宜作为青春期启动的诊断标志物。
要点
- 健康女婴血清DLK1在出生第一年显著下降(17.6降至9.9 ng/mL,P=0.020)。
- DLK1与出生体重(r=-0.220,P=0.044)和体脂百分比(r=-0.503,P<0.001)呈负相关。
- GnRHa治疗不改变中枢性性早熟女童的DLK1水平;DLK1不宜作为青春期启动诊断标志物。
核心结论
- 循环DLK1水平在婴儿期急剧下降,在青春期发育过程中下降较不明显。
- 由于个体间变异大,DLK1不宜作为青春期启动的诊断标志物。
- DLK1与出生体重和体脂百分比呈负相关。
研究设计与样本
- 三项纵向研究:健康足月单胎女婴(n=85)、健康围青春期女童(n=15)、中枢性性早熟女童GnRHa治疗前后(n=15)。
- 体脂百分比采用Slaughter方程计算,血清DLK1采用酶联免疫吸附测定法检测。
主要发现
- 健康女婴血清DLK1在出生第一年显著下降(17.6降至9.9 ng/mL,P=0.020)。
- DLK1与出生体重呈负相关(r=-0.220,P=0.044),与体脂百分比呈负相关(r=-0.503,P<0.001)。
- DLK1从青春期启动前1年至青春期启动后首次检查时下降(10.4降至9.2 ng/mL,P=0.004),至末次青春期评估时亦下降(10.4降至9.8 ng/mL,P=0.006)。
- GnRHa治疗不影响DLK1水平。
临床怎么用
- 作者认为,由于个体间变异大,DLK1不宜作为青春期启动的诊断标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Delta-like non-canonical notch ligand 1 (DLK1) is negatively associated with bodyweight. DLK1 pathogenic variants cause central precocious puberty (CPP) and obesity, suggesting that DLK1 links the well-established association between higher body mass index and earlier pubertal onset. However, little is known about the trajectories of circulating DKL1 in healthy girls as well as in girls with precocious puberty. OBJECTIVE: To evaluate longitudinal changes in circulating DLK1 concentrations in (1) full-term, singleton healthy infant girls, (2) healthy girls during pubertal transition, and (3) girls with CPP during treatment with gonadotropin-releasing hormone agonist (GnRHa). METHODS: Three longitudinal studies of (1) healthy infant girls (n = 85), (2) healthy peripubertal girls (n = 15), and (3) girls with CPP before and after GnRHa treatment (n = 15). Body fat percentage calculated using the Slaughter equation, and serum concentrations of DLK1 using enzyme-linked immunosorbent assay. RESULTS: Serum concentration of DLK1 in healthy infant girls declined significantly through the first year of life (17.6 to 9.9 ng/mL, P = .020). DLK1 was inversely correlated with birth weight and BF%: r = -0.220, P = .044, and r = -0.503, P < .001, respectively. DLK1 declined from 1 year prior to pubertal onset to time of first examination after pubertal onset (10.4 to 9.2 ng/mL, P = .004), as well as to time at the last pubertal evaluation (10.4 to 9.8 ng/mL, P = .006). DLK1 levels were not affected by GnRHa treatment. CONCLUSION: Circulating DLK1 levels declined steeply during infancy and were less pronounced through pubertal development. Due to considerable interindividual variation, DLK1 is not useful as a diagnostic marker of pubertal onset. Importantly, DLK1 was negatively associated with birth weight and body fat percentage.
引用
- Vilmann L, Sørensen K, Busch AS, et al. Serum DLK1 During Minipuberty and Pubertal Transition in Healthy Girls and in Girls With Precocious Puberty. J Clin Endocrinol Metab. 2025. PMID: 39468766. doi:10.1210/clinem/dgae762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。